joa development group inc.

85 hunter street
ossining, new york 10562

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 28, 2014

NYS DOS ID#
4568672

County
WESTCHESTER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - JOA DEVELOPMENT GROUP INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • IAB Tech Lab Launches Blockchain Working Group
    Monday Sep 18, 2017

    GroupM, Kochava, MetaX, and Nyiax have become member companies in an IAB Tech Lab working group that launched Monday focused on blockchain and explore ways to use it in digital technology. ShailleySingh leads the group. The working group will initially design ways to educate the industry, set priorities for business use cases and develop standards and best practices. 

    Source: Media Post: Search Marketing Daily
  • Solar Developers and Panel Makers Clash Over Tariff Request
    By DIANE CARDWELL - Tuesday Aug 15, 2017

    Troubled domestic manufacturers say cheap Chinese products have undercut their own, but industry groups are urging a trade panel to reject sanctions.

    Source: NYT > Home Page
  • Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
    By Caroline Chen - Tuesday Oct 17, 2017

    Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.

    Source: SFGATE.com: Business and Technology News
  • This New Ad Campaign Shows The Faces Of Global Poverty–And Opportunity
    By Eillie Anzilotti - Tuesday Oct 17, 2017

    For World Poverty Day, nonprofit venture capital fund Acumen debuts a series of portraits of people living on less than $5 a day–and show how the projects it’s funded are helping.

    “We live in a moment right now when divides between people are sharp, and growing,” Jacqueline Novogratz, founder and CEO of the nonprofit venture capital fund Acumen, which invests philanthropic capital to support business growth in the developing world. But, she adds, if you pause and look more closely at people, those divides start to blur, then fall away entirely.

    Read Full Story

    Source: Fast Company
  • Restaurant Review: The Pool Strives to Deal With Its Famous Dining Room
    By PETE WELLS - Tuesday Oct 17, 2017

    Changes to the landmark interior of the former Four Seasons create challenges for the new restaurant from Major Food Group.

    Source: NYT > Home Page
  • Cancer drug research moving fast in immunotherapy field
    By Michelle Fay Cortez - Tuesday Sep 5, 2017

    The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.

    Source: SFGATE.com: Business and Technology News